nafamostat has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In vivo, orthotopic pancreatic cancer mice (BALBc nu/nu) were divided into four groups: control (n = 13), NM (n = 13), GEM/nPTX (n = 13), and triple combination (n = 13)." | 1.43 | New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. ( Haruki, K; Horiuchi, T; Iwase, R; Ohashi, T; Saito, N; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horiuchi, T | 1 |
| Uwagawa, T | 1 |
| Shirai, Y | 1 |
| Saito, N | 1 |
| Iwase, R | 1 |
| Haruki, K | 1 |
| Shiba, H | 1 |
| Ohashi, T | 1 |
| Yanaga, K | 1 |
1 other study available for nafamostat and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2016 |